Gülşah ELBÜKEN, Onur ÖZTÜRK, Bahadir YAZİCİOGLU, Recep AKTİMUR, Zulay KAZAK, Ilsen Semiha KECECİ, Sema KOLCU-BULBUL, Bora ÖZAN, MEHMET DERYA DEMİRAĞ

Primary Hyperparathyroidism Presented with Peripheral Brown Tumor in the Oral Cavity: A Case Report

Brown tumor is a non-neoplastic lesion which resulting from abnormal bone metabolism caused by hyperparathyroidism. We report a rare case of peripheral brown tumor related with primary hyperparathyroidism which simulating a peripheral giant cell granuloma of the jaws.

PDF

___

1. MacKenzie-Feder J, Sirrs S, Anderson D, Sharif J, Khan A. Primary Hyperparathyroidism: An Overview. Int J Endocrinol. 2011;2011:251410.

2. Felder EA, Kandil E. Primary hyperparathyroidism. Otolaryn Clin of North Am. 2010; 43(2):417-32.

3. Marx SJ. Hyperparathyroid and hypoparathyroid disorders. N Engl J Med. 2000;343 (25):1863-75.

4. Shane E. Clinical review 122: parathyroid carcinoma. J Clin Endocr Metab. 2001;86(2):485-93.

5. Bilezikian JP. Nephrolithiasis in primary hyperparathyroidism. In: Coe FL, Favus MJ, Pak CYC, Parks JH, Preminger GM, eds. Kidney Stones: medical and surgical treatment. Philadelphia: Lippincott-Raven.1996;783-802.

6. Fraser WD. Hyperparathyroidism. The Lancet. 2009;374(9684):145-58.

7. Khan AA, Bilezikian JP, Potts JTJ. The diagnosis and management of asymptomatic primary hyperparathyroidism revisited. J Clin Endocr Metab. 2009;15(5):333-4.

8. Bandeira F, Griz L, Chaves N, Carvalho NC, Borges LM, Lazaretti-Castro M, Borba V, de Castro LC, Borges JL, Bilezikian J. Diagnosis and management of primary hyperparathyroidism-a scientific statement from the Department of Bone Metabolism, the Brazilian Society for Endocrinology and Metabolism. Arq Bras Endocrinol Metabol. 2013;57(6):406-24.

9. Cope O. The study of hyperparathyroidism at the Massachusetts General Hospital. N Engl J Med. 1966;274(21):1174-82.

10. Silverberg SJ. Non-classical target organs in primary hyperparathyroidism. J Bone Miner Res. 2002;17(2):117-25.

11. Wishart J, Horowitz M, Need A, Nordin BE. Relationship between forearm and vertebral mineral density in postmenopausal women with primary hyperparathyroidism. Arch Intern Med. 1990;150(6):1329-31.

12. Khan AJH, Pender A, Wei X, Potter M. I-cell disease (mucolipidosis II) presenting as neonatal fractures: a case for continued monitoring of serum parathyroid hormone levels. ClinPed Endocrinol. 2008;17(3):81-5.

13. Bramley P, Dwyer D. Primary hyperparathyroidism. Its effect on a mother and her children. Oral Surgery Oral Med Oral Pathol. 1970;30(4):464-71.

14. Som PM, Lawson W, Cohen BA. Giant-cell lesions of the facial bones. Radiology. 1983;147(1):129-34.

15. Palot Manzil FF, Bhambhvani P, Vattoth S, Subedi SK, Bag AK, O'Malley JP. Primary hyperparathyroidism-related brown tumors mimicking other giant cellcontaining skeletal tumors: role of correlative imaging in diagnosis. J Nucl Med Technol. 2013;41(1):46-8.

16. Shang ZJ, Li ZB, Chen XM, Li JR, McCoy JM. Expansile lesion of the mandible in a 45-year-old man. J Oral Maxillofac Surg. 2003;61(5):621-5.

17. Triantafillidou K, Zouloumis L, Karakinaris G, Kalimeras E,Iordanidis F. Brown tumors of the jaws associated with primary or secondary hyperparathyroidism. A clinical study and review of the literature. Am J of Otolaryngol. 2006;27(4):281-6.

18. Martinez-Gavidia EM, Bagan JV, Milian- Masanet MA, Lloria de A, Perez-Valles A. Highly aggressive Brown tumour of the maxilla as first manifestation of primary hyperparathyroidism. Int J Oral Maxillofac Surg. 2000;29(6):447-9.

19. Daniels JS. Primary hyperparathyroidism presenting as a palatal Brown tumor. Oral Surgery Oral Med Oral Pathol Oral Radiol Endoc. 2004;98(4):409-13.

20. Guney E, Yigitbasi OG, Bayram F, Ozer V, Canoz O. Brown tumor of the maxilla associated with primary hyperparathyroidism. Auris Nasus Larynx 2001;28(4):369-72.

21. Keyser JS, Postma GN. Brown tumor of the mandible. Am J Otolaryngol. 1996;17(6):407-10.

22. Dusunsel R, Guney E, Gunduz Z, Poyrazoglu MH, Yigitbasi O, Kontas O. Maxillary Brown tumor caused by secondary hyperparathyroidism in a boy. Pediatr Nephrolog. 2000;14(6):529-30.

23. Kulak CA, Bandeira C, Voss D, Sobieszczyk SM, Silverberg SJ, Bandeira F, Bilezikian JP. Marked improvement in bone mass after parathyroidectomy in osteitis fibrosa cystica. J Clin Endocrinol Metab. 1998;83(3):732-5.

24. Agarwal G, Mishra SK, Kar DK, Singh AK, Arya V, Gupta SK, Mithal A. Recovery pattern of patients with osteitis fibrosa cystica in primary hyperparathyroidism after successful parathyroidectomy. Surgery. 2002;132(6):1075-83.

25. Rothe HM, Liangos O, Biggar P, Petermann A, Ketteler M. Cinacalcet treatment of primary hyperparathyroidism. Int J Endocrinol. 2011;2011:415719.

26. Duntas LH, Stathatos N. Cinacalcet as alternative treatment for primary hyperparathyroidism: achievements and prospects. Endocrine. 2011;39(3):199-204.

27. Peacock M, Bolognese MA, Borofsky M, Scumpia S, Sterling LR, Cheng S, Shoback D. Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study. J Clin Endocrinol Metab. 2009;94(12):4860-7.

28. Khan AA, Bilezikian JP, Kung A, Dubois SJ, Standish TI, Syed ZA. Alendronate therapy in men with primary hyperparathyroidism. Endocr Pract. 2009;15(7):705-13.

29. Chow CC, Chan WB, Li JK, Chan NN, Chan MH, Ko GT, Lo KW, Cockram CS. Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab. 2003;88(2):581-7.

30. Parker CR, Blackwell PJ, Fairbairn KJ, Hosking DJ. Alendronate in the treatment of primary hyperparathyroid-related osteoporosis: a 2-year study. J Clin Endocrinol Metab. 2002;87(10):4482-9.